If you have MASH, GLP-1 medications may help treat the condition. Set yourself up for success with expert advice on diet, exercise, dose scheduling, and more.

Learn about semaglutide’s effectiveness and clinical trial results and whether it could be right for you in your MASH treatment plan.

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...

As Eli Lilly and Novo Nordisk scramble to bring an oral glucagon-like peptide 1 (GLP-1) receptor agonist to market for obesity, much smaller potential rival Structure Therapeutics spotlighted positive ...

Introducing Ozempic, a groundbreaking GLP-1 agonist now making waves in India! This innovative treatment emulates a natural ...

The managing director of Novo Nordisk India on Ozempic’s delayed launch in India, leading the fight against diabetes and ...

Denmark: Novo Nordisk and Akero Therapeutics have announced that Novo Nordisk's acquisition of Akero has been completed.With ...

MedPage Today brought together three hepatology experts for a virtual roundtable discussion on metabolic ...

The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...

This report, published by Towards Healthcare, a sister firm of Precedence Research offers a comprehensive analysis of the rapidly expanding Oral GLP-1 market. It highlights the market’s accelerating ...

Altimmune, Inc. nears key MASH data for pemvidutide—learn investor risks, potential rewards, and what the upcoming results ...